JAMA Cardiology

Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Meta-analysis of randomised trialsInterventions

Declared ties to: Boehringer Ingelheim, Eli Lilly for the EMPA-KIDNEY, Novo Nordisk for the ASCEND-PLUS and 1 more

The paper